相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem/progenitor cells
Sadegh Babashah et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells
Haojian Zhang et al.
PROTEIN & CELL (2013)
The Wnt Pathway: Emerging Anticancer Strategies
Aman Gupta et al.
RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY (2013)
Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells
Hui-Fen Liao et al.
BIOMEDICINE & PHARMACOTHERAPY (2012)
Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis
Hongfeng Yuan et al.
BLOOD (2012)
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice
Christoph Walz et al.
BLOOD (2012)
Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib
Ling Li et al.
CANCER CELL (2012)
Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through β-catenin signaling
Wenxia Su et al.
EXPERIMENTAL HEMATOLOGY (2012)
Tyrosine kinase inhibitors in acute and chronic leukemias
Maro Ohanian et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia
Gunhild Keller-v. Amsberg et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression
Christian Schuerch et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Scd1 Plays a Tumor-Suppressive Role in Survival of Leukemia Stem Cells and the Development of Chronic Myeloid Leukemia
Haojian Zhang et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells
Y. Yu et al.
LEUKEMIA (2012)
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
Oliver Hantschel et al.
NATURE CHEMICAL BIOLOGY (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Chronic myeloid leukemia: Archetype of the impact of targeted therapies
R. Nasr et al.
PATHOLOGIE BIOLOGIE (2012)
β-Arrestin2 mediates the initiation and progression of myeloid leukemia
Mark Fereshteha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML
G. Vignir Helgason et al.
BLOOD (2011)
Evolution of Therapies for Chronic Myelogenous Leukemia
Fabio P. S. Santos et al.
CANCER JOURNAL (2011)
Targeted Blockage of Signal Transducer and Activator of Transcription 5 Signaling Pathway with Decoy Oligodeoxynucleotides Suppresses Leukemic K562 Cell Growth
Xiaozhong Wang et al.
DNA AND CELL BIOLOGY (2011)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
Bing Long et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2011)
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
Christian Hurtz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia
A. Samanta et al.
LEUKEMIA (2011)
The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis
B. G. Mar et al.
LEUKEMIA (2011)
Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors
Bruno Calabretta et al.
LEUKEMIA & LYMPHOMA (2011)
Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis
Olof Radmark et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
Timothy P. Hughes et al.
BLOOD (2010)
Hedgehog pathway activation in chronic myeloid leukemia A promise for a novel combination therapeutic approach?
Zainab Jagani et al.
CELL CYCLE (2010)
Pleural effusions due to dasatinib
Anupama G. Brixey et al.
CURRENT OPINION IN PULMONARY MEDICINE (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Critical molecular pathways in cancer stem cells of chronic myeloid leukemia
Y. Chen et al.
LEUKEMIA (2010)
TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Kazuhito Naka et al.
NATURE (2010)
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia.
Claude Preudhomme et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Chronic Myeloid Leukemia: A Historical Perspective
John M. Goldman
SEMINARS IN HEMATOLOGY (2010)
Molecular and cellular bases of chronic myeloid leukemia
Yaoyu Chen et al.
PROTEIN & CELL (2010)
Epidemiology of chronic myeloid leukaemia (CML)
Maren Rohrbacher et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
Fausto Castagnetti et al.
BLOOD (2009)
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Martin C. Mueller et al.
BLOOD (2009)
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Gianantonio Rosti et al.
BLOOD (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Proteasome Inhibition Causes Regression of Leukemia and Abrogates BCR-ABL-Induced Evasion of Apoptosis in Part through Regulation of Forkhead Tumor Suppressors
Zainab Jagani et al.
CANCER RESEARCH (2009)
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells
Cristian Bellodi et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Chronic Myeloid Leukemia Stem Cells: Now on the Run
John M. Goldman
JOURNAL OF CLINICAL ONCOLOGY (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia
Y. Hu et al.
LEUKEMIA (2009)
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
Chen Zhao et al.
NATURE (2009)
IFNα activates dormant haematopoietic stem cells in vivo
Marieke A. G. Essers et al.
NATURE (2009)
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
Yaoyu Chen et al.
NATURE GENETICS (2009)
Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?
Elias Jabbour et al.
MAYO CLINIC PROCEEDINGS (2009)
The Chronic Myeloid Leukemia Stem Cell
Emma Nicholson et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation
Christine Dierks et al.
CANCER CELL (2008)
PML targeting eradicates quiescent leukaemia-initiating cells
Keisuke Ito et al.
NATURE (2008)
Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo
Chen Zhao et al.
CANCER CELL (2007)
How I treat chronic myeloid leukemia in the imatinib era
John M. Goldman
BLOOD (2007)
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Thomas O'Hare et al.
BLOOD (2007)
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study
Arghya Ray et al.
BLOOD (2007)
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
Miriam Puttini et al.
CANCER RESEARCH (2006)
Janus kinase 2: A critical target in chronic myelogenous leukemia
Ajoy K. Samanta et al.
CANCER RESEARCH (2006)
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Mhairi Copland et al.
BLOOD (2006)
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients; correlation with clonal cytogenetic evolution but not response to therapy
SG Willis et al.
BLOOD (2005)
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
CHM Jamieson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Wnt/β-catenin signaling pathway as novel cancer drug targets
HH Luu et al.
CURRENT CANCER DRUG TARGETS (2004)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy
A Hochhaus et al.
LEUKEMIA (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
分享论文
